The clinical application for another four-specific antibody from Baili Pharmaceuticals was accepted.

Screenshot Source: CDE Official Website It is well known that monosexual monoclonal antibodies are the first widely used cancer immunotherapy, such as anti-PD-1/PD-L1 antibodies.
, dual-specific antibodies that can target two targets at the same time began to receive attention, such as the plelintomo double resistance (blinatumomab) that targeted CD19/CD3.
to further improve the therapeutic effect of antibodies, scientists have begun to study multisexual antibodies, including three-specific antibodies, four-specific antibodies and so on.
Pharmaceutical Group was founded in 1996, the company's founder is Dr. Zhu Yi.
, according to the official website of the company, innovative antibody drugs are one of its main research and development areas.
antibody is an important direction in the antibody drug development pipeline.
GNC-039, which was accepted by CDE, is a four-specific antibody injection for a new class of 1 drug.
it is worth noting that this is not the first time that Leigh Pharmaceuticals has submitted a clinical application for a four-specific antibody in the study of the drug.
In September this year, Baillie Pharmaceuticals' class 1 new drug GNC-038 ivy antibody injections obtained a clinically implied license in China for the treatment of recurring or recurring non-Hodgkin's lymphoma (R/R NHL), recurring or resuscitated acute lymphoblastic leukemia (R/R ALL), resuscitated or metastatic solid tumors (Expand reading: Ivy Antibodies!). Leigh Pharmaceuticals is once again in the study of anti-cancer drugs approved clinically).
According to a Leigh Pharmaceuticals press release, GNC-038 is the first candidate to enter the clinic under the NTC platform, a "targeted immune" antibody for a four-specific structure that can target four antigens simultaneously and is clinically intended for the treatment of hematomas and solid tumors.
, GNC-038 is the world's first successful clinically approved four-specific antibody, according to a New York-based pharmaceutical press release.
and the clinical application for GNC-039 was accepted by CDE, meaning that Leigh Pharmaceuticals has made another advance in the field of four specific antibodies.
addition to the two four-specific antibody candidates mentioned above, there are two-specific antibodies and antibody association drugs (ADCs) in the pipeline for the development of antibody immunotherapy.
Two of these dual-specific antibodies have entered clinical research in China: one is SI-B001 dual-specific antibody injection, has been approved for clinical studies of local late-stage or metastatic endoscopic tumors, including esophageal squamous cancer, lung scale cancer, triple-yin breast cancer, head and neck squamous cancer, colorectal cancer, etc.; The other is si-B003 dual-specific antibody injections, which are approved for clinical study adaptation for the treatment of localized advanced, relapsed or metastatic solid tumors, including renal cell carcinoma, colorectal cancer, melanoma, non-small cell lung cancer, urethra cancer, etc.
addition, there are several drug candidates on the Poly Pharmaceuticals GNC platform at the declaration and preclinical research stages.
the Product Pipeline (Screenshot Source: Baili Pharmaceuticals Official Website) Reference: 1. China's State Drug Administration Drug Review Center. Retrieved Oct 15, 2020, from s2, the world's first four-specific antibody GNC-038 has been approved clinically in China. Retrieved Sep 02, 2020, from Source: Medical Mission Hills.